SRSF1 and small cell lung carcinoma: Further, SRSF1 CN gain was determined to be 30% (8/27 SCLC patients) in a re-analysis of the available WES data published from a previous Caucasian SCLC patient cohort–a result very similar between both Caucasian SCLC cohorts [3].